Application of KLRB1 gene in treatment of breast cancer

By developing necrotizing apoptosis-related models and determining the tumor suppression effect of KLRB1, the problem of underutilization of necrotizing apoptosis in breast cancer is solved, and a new treatment method for breast cancer is provided, which improves the treatment effect of patients.

CN118910265APending Publication Date: 2024-11-08TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411279969.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The specific role of necrotizing apoptosis in breast cancer immunotherapy has not been fully explored in the prior art, and there is a lack of effective treatment methods and biomarkers for the disease.

Method used

By developing necrotizing apoptosis-related models, KLRB1 is determined as a key tumor suppressor, and its expression patterns and functions in breast cancer are studied. As a therapeutic target for breast cancer, drugs or kits that upregulate the expression level of KLRB1 genes are developed. Used to regulate macrophage activity and immunotherapy.

Benefits of technology

It provides a new direction for the treatment of breast cancer, improves the treatment effect of patients, changes traditional treatment methods, and improves the effectiveness of immunotherapy by clarifying advanced treatment methods of necrotizing apoptosis pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910265A_ABST
    Figure CN118910265A_ABST
Patent Text Reader

Abstract

The invention relates to application of a KLRB1 gene in treatment of breast cancer, in particular to application of the KLRB1 gene as a target in preparation or screening of breast cancer treatment products. According to the method, TCGA and other data sets are used for bioinformatics analysis, and NMF and CoxBoost algorithms are used for developing necroptosis related modes and models; through in-vitro verification, a model related to necroptosis is developed, and KLRB1 is determined as a key tumor inhibition factor; mutation characteristics, immune characteristics and molecular functions of the KLRB1 are studied; in-vitro experiments further verify that the KLRB1 related to necroptosis is used as a potent tumor inhibition factor in breast cancer and has the effect of regulating the activity of macrophages, and the KLRB1 is a determinant of immunotherapy. The traditional Chinese medicine composition paves a way for advanced treatment methods of necroptosis, so that the treatment effect of patients is improved, and the treatment mode of breast cancer is changed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of molecular biology and clinical application, and in particular to the application of KLRB1 gene in treating breast cancer. Background Art

[0002] Breast cancer is a complex and diverse disease that affects millions of people worldwide. It is the most common type of cancer in women and is responsible for a significant number of cancer-related deaths. Many genetic, environmental, and lifestyle factors play a role in the development and spread of breast cancer. Over the years, a great deal of research has been conducted to identify the underlying causes of breast cancer and to develop effective treatment options. Immunotherapy is an advanced treatment option that uses the body's immune system to fight cancer cells. It involves the use of various approaches and drugs to boost the immune system and kill cancer cells. Immunotherapy has shown great promise in the treatment of breast cancer, giving patients new hope and potentially improving treatment outcomes.

[0003] Necroptosis is a type of programmed cell death that is distinct from necrosis and apoptosis. It is a tightly controlled process that is important in many clinical and physiological situations. The signaling pathways activated during necroptosis include receptor interacting protein kinase 1 (RIPK1), receptor interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain-like protein (MLKL). The coordinated actions of these signaling molecules ultimately lead to cell death. Necroptosis has been shown to be associated with a variety of diseases, such as cancer, neurological diseases, and inflammatory diseases. Necroptosis has emerged as a promising therapeutic target and predictor of immunotherapy success in the context of breast cancer. Understanding the basic mechanisms of necroptosis and how it promotes breast cancer development may help develop new treatments and identify biomarkers for personalized medicine. Necroptosis is widely involved in cancer development. However, the specific role of necroptosis in immunotherapy for breast cancer has not been explored.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] In order to make up for the deficiencies of the prior art, the purpose of the present invention is to provide an application of KLRB1 gene in the treatment of breast cancer.

[0006] In the present invention, it is intended to establish a link between necroptosis and immunotherapy for breast cancer. A necroptosis-related model was developed and KLRB1 (killer cell lectin like receptor B1, Gene ID: 3820) was identified as a key tumor suppressor. The role of necroptosis-related KLRB1 in breast cancer was further explored as a potent tumor suppressor and immunotherapy determinant. In the present invention, the expression pattern of KLRB1 in breast cancer tissue was studied and the importance of these expression patterns for prognosis was evaluated. In addition, the present invention will study the functional effects of KLRB1 in animal models and breast cancer cell lines to provide insights into its potential utility as a therapeutic target. The research of the present invention aims to provide more information on the genetic mechanism of this disease by clarifying the role of necroptosis-related KLRB1 in breast cancer. Ultimately, the research of the present invention may pave the way for the development of advanced treatments targeting necroptosis pathways, thereby improving patient treatment outcomes and changing the treatment of breast cancer.

[0007] The first aspect of the present invention provides an application of a KLRB1 gene in treating breast cancer, and an application of the KLRB1 gene as a target in preparing or screening a product for treating breast cancer.

[0008] Preferably, the breast cancer treatment product is a drug or a kit for up-regulating the expression level of the KLRB1 gene, or a drug or a kit for increasing the content or activity of the KLRB1 protein.

[0009] Preferably, the breast cancer treatment product comprises a nucleic acid molecule that upregulates the expression level of the KLRB1 gene in tumor cells.

[0010] Preferably, the nucleic acid molecule comprises: any one or more combinations of siRNA, shRNA, ASO, miRNA or oligonucleotides of the KLRB1 gene.

[0011] Preferably, the siRNA sequence of the KLRB1 gene is shown in any one of SEQ ID NOs: 1-2.

[0012] Preferably, the KLRB1 gene acts as a potent tumor suppressor, regulates macrophage activity, and plays an immunotherapeutic role in the treatment of breast cancer.

[0013] In a second aspect, the present invention provides a nucleic acid molecule drug for treating breast cancer, wherein the nucleic acid molecule drug contains a nucleic acid molecule or a pharmaceutically acceptable salt thereof that upregulates the expression level of the KLRB1 gene in tumor cells.

[0014] Preferably, the nucleic acid molecule for upregulating the expression level of KLRB1 gene in tumor cells comprises: any one or more combinations of siRNA, shRNA, ASO, miRNA or oligonucleotides of KLRB1 gene.

[0015] Preferably, the siRNA sequence of the KLRB1 gene is shown in any one of SEQ ID NOs: 1-2.

[0016] The third aspect of the present invention provides a pharmaceutical composition for treating breast cancer, wherein the pharmaceutical composition comprises the above-mentioned nucleic acid molecule drug for treating breast cancer and a pharmaceutically acceptable carrier.

[0017] Beneficial effects:

[0018] The present invention uses TCGA, METABRIC, GSE103091, GSE159956 and GSE96058 data sets for bioinformatics analysis, and NMF and CoxBoost algorithms are used to develop necroptosis-related patterns and models respectively; through in vitro verification, a model related to necroptosis is developed, and KLRB1 is determined as a key tumor suppressor; the mutation characteristics, immune characteristics and molecular functions of KLRB1 are studied; and in vitro experiments further verify that necroptosis-related KLRB1 acts as a potent tumor suppressor and regulates macrophage activity in breast cancer, and KLRB1 is a determinant of immunotherapy. The present invention paves the way for advanced treatment methods of necroptosis pathways, thereby improving the treatment effect of patients and changing the treatment of breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0020] Figure 1 The figure is the development result of necroptosis-related patterns; A is the HR value of necroptosis-related genes; B is the cophenetic coefficient of different patterns; C is the PCA analysis of necroptosis-related patterns; D is the survival curve of necroptosis-related patterns; E is the expression pattern of necroptosis-related genes in necroptosis-related patterns.

[0021] Figure 2Figure 1 is the annotation result diagram of necroptosis-related patterns; A is the differentially expressed genes (DEGs) of necroptosis-related patterns; B is the HR value of differentially expressed genes; C is the gene set enrichment analysis (GSEA) of differentially expressed genes.

[0022] Figure 3 The figure is the identification result of KLRB1; A is the CoxBoost dimension reduction of differentially expressed genes; B is the survival curve of KLRB1-related groups in TCGA; C is the survival curve of KLRB1-related groups in METABRIC; D is the survival curve of KLRB1-related groups in GSE103091; E is the survival curve of KLRB1-related groups in GSE159956; F is the survival curve of KLRB1-related groups in GSE96058.

[0023] Figure 4 The figure is the mutation characteristic result of KLRB1; A is the chromosome gain and loss of KLRB1 related groups; B is the mutation probability of the mutation site of KLRB1 related groups; C is the G score of the mutation site of KLRB1 related groups.

[0024] Figure 5 The figure is the immune characteristic result of KLRB1; A is the correlation between KLRB1 and immune regulatory factors; B is the correlation between KLRB1 and ESTIMATE score; C is the relative activity of immune cells in the KLRB1-related group.

[0025] Figure 6 Annotation of KLRB1 - Gene set enrichment analysis (GSEA) result diagram of KLRB1.

[0026] Figure 7 The figure is the experimental verification result of KLRB1; wherein, A is the qPCR experiment for screening the best siRNA target; B is the CCK8 experiment of KLRB1; C is the EdU experiment of KLRB1; D is the statistical analysis of the EdU experiment; E is the Transwell experiment of KLRB1; F is the statistical analysis of the Transwell experiment; G is the co-culture Transwell experiment of KLRB1; H is the statistical analysis of the co-culture Transwell experiment. DETAILED DESCRIPTION

[0027] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0028] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form also includes the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0029] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0030] Application of KLRB1 gene in the treatment of breast cancer, and application of KLRB1 gene as a target in the preparation or screening of breast cancer treatment products.

[0031] The breast cancer treatment product is a drug or kit that upregulates the expression level of the KLRB1 gene, or a drug or kit that increases the content or activity of the KLRB1 protein.

[0032] The breast cancer treatment product contains a nucleic acid molecule that upregulates the expression level of the KLRB1 gene in tumor cells.

[0033] The nucleic acid molecule comprises any one or more combinations of siRNA, shRNA, ASO, miRNA or oligonucleotides of the KLRB1 gene.

[0034] The siRNA sequence of the KLRB1 gene is shown in any one of SEQ ID NOs: 1-2.

[0035] The KLRB1 gene acts as a potent tumor suppressor, regulates macrophage activity, and plays a role in immunotherapy in breast cancer treatment.

[0036] A nucleic acid molecule drug for treating breast cancer, comprising a nucleic acid molecule or a pharmaceutically acceptable salt thereof that upregulates the expression level of KLRB1 gene in tumor cells.

[0037] The nucleic acid molecule for upregulating the expression level of KLRB1 gene in tumor cells comprises: any one or more combinations of siRNA, shRNA, ASO, miRNA or oligonucleotide of KLRB1 gene.

[0038] The siRNA sequence of the KLRB1 gene is shown in any one of SEQ ID NOs: 1-2.

[0039] A pharmaceutical composition for treating breast cancer, comprising the above-mentioned nucleic acid molecule drug for treating breast cancer and a pharmaceutically acceptable carrier.

[0040] Example 1: Data Collection

[0041] TCGA, METABRIC, GSE103091, GSE159956, and GSE96058 datasets were collected for subsequent analysis. TCGA is a comprehensive and publicly available resource containing genomic, transcriptomic, and clinical data for various cancer types. METABRIC is a large-scale database designed to classify breast cancer according to molecular subtypes and provide valuable genomic and clinical information. GSE103091, GSE159956, and GSE96058 are from GEO. GEO contains many high-throughput gene expression datasets, including microarray and next-generation sequencing data. Researchers can access and analyze these datasets to gain insight into gene expression patterns and regulatory mechanisms in different biological conditions and diseases. The GEO database is an important resource for studying the molecular basis of diseases, identifying potential biomarkers, and discovering new therapeutic targets.

[0042] Example 2: Development of necroptosis-related models

[0043] Necroptosis-related genes were collected from previous publications. The NMF algorithm was used to determine the necroptosis-related patterns. The NMF algorithm, or non-negative matrix factorization, is a popular unsupervised learning technique for dimensionality reduction and feature extraction. It is particularly suitable for analyzing non-negative data such as images, text, and gene expression data. The NMF algorithm decomposes a non-negative matrix into two lower-rank non-negative matrices that can be interpreted as basis vectors and coefficients. These basis vectors and coefficients can be used to reconstruct the original matrix or extract meaningful features. NMF has a wide range of applications in image processing, text mining, and bioinformatics. The R package survival was used to generate survival curves for necroptosis-related patterns. The R packages pheatmap and ComplexHeatmap were used to generate expression patterns of necroptosis-related genes in necroptosis-related patterns.

[0044] The results of the development of necroptosis-related models are shown in Figure 1 After univariate Cox regression analysis, the HR of necroptosis-related genes showed that nine genes were risky, while five genes were favorable ( Figure 1 Using the NMF algorithm, breast cancer patients are clustered into different patterns ( Figure 1 B), where the cophenetic coefficient is 2, achieving the highest clustering ability. PCA of necroptosis-related patterns shows that breast cancer patients are separated ( Figure 1C). The survival curves of the necroptosis-related patterns showed that the survival time of breast cancer patients in pattern 1 was significantly reduced ( Figure 1 D). The expression patterns of necroptosis-related genes in these models are as follows Figure 1 As shown in E.

[0045] Example 3: Annotation of necroptosis-related patterns

[0046] The R package EnhancedVolcano generated a volcano plot of differentially expressed genes (DEGs) in necroptosis-related patterns. Gene set enrichment analysis (GSEA) was performed on these DEGs. GSEA is a computational method used to determine whether a predefined set of genes shows statistically significant differences between two biological states. GSEA can be used to analyze gene expression data and identify biological pathways or gene sets associated with a specific phenotype or condition. It is a powerful tool for understanding the underlying biological mechanisms and pathways involved in a given disease or experimental condition.

[0047] The annotation results of necroptosis-related patterns are shown in Figure 2 . Figure 2 The volcano plot in A shows the differentially expressed genes (DEGs) in the necroptosis-related pattern. All significantly upregulated DEGs are favorable ( Figure 2 B). GSEA analysis of DEGs revealed that immune and inflammatory responses were suppressed ( Figure 2 C).

[0048] Example 4: Identification of KLRB1

[0049] The CoxBoost algorithm was used to reduce the dimension of DEGs. This method resulted in 11 powerful genes, of which KLRB1 was the most significant. In the TCGA dataset, the survival curves of the groups associated with KLRB1 showed that the survival time of breast cancer patients in the KLRB1 high expression group was significantly prolonged. Similar results were also verified in the METABRIC, GSE103091, GSE159956, and GSE96058 datasets.

[0050] The identification results of KLRB1 are shown in Figure 3 After CoxBoost dimension reduction of DEGs, 11 effective genes were obtained, among which KLRB1 was the most significant ( Figure 3 A in ). The survival curve of the KLRB1-related groups in TCGA showed that the survival time of breast cancer patients in the KLRB1 high expression group was significantly prolonged ( Figure 3In the METABRIC, GSE103091, GSE159956, and GSE96058 datasets, the survival time of breast cancer patients in the KLRB1 high expression group was also significantly prolonged ( Figure 3 CF in ).

[0051] Example 5: Mutational characteristics of KLRB1

[0052] The mutational signature of KLRB1 was explored using the R package maftools. maftools is an R package that provides a set of functions for analyzing and visualizing somatic mutation data in cancer genomics studies. It allows users to perform various tasks such as mutation annotation, visualization of mutation maps, identification of significantly mutated genes, and exploration of mutational signatures. maftools is widely used in cancer genomics research to gain insight into the genetic alterations that drive cancer development.

[0053] The mutational characteristics of KLRB1 are shown in Figure 4 Chromosomal gains and losses in KLRB1-related groups Figure 4 As shown in A. The mutation probability of the mutation sites in the KLRB1-related groups showed that 17q12, 8p11.23, and 11q13.3 were frequently gained, while 17q12, 1p36.13, and 11q23.2 were frequently lost ( Figure 4 The G score of the mutation site shows the overall mutation pattern ( Figure 4 C).

[0054] Example 6: Immunological characteristics of KLRB1

[0055] The R packages pheatmap and ComplexHeatmap generated the correlation between KLRB1 and immune regulators. The R package estimate was used to calculate the ESTIMATE score. estimate is a tool for estimating tumor purity, stromal score, and immune score in tumor samples from gene expression data. It enables quantitative assessment of the tumor microenvironment and can be used to study tumor-immune interactions and their impact on cancer progression and response to therapy. The TIMER algorithm was used to calculate the abundance of immune cells. The TIMER algorithm is a computational tool for analyzing tumor-immune interactions. It estimates the level of immune infiltration in tumor samples based on gene expression data. This algorithm can be used to study the tumor microenvironment and its impact on cancer progression and response to immunotherapy.

[0056] The results of KLRB1 immune characterization are shown in Figure 5 KLRB1 is significantly associated with multiple immune regulatory factors such as BTN3A2, VTCN1, CD276, VEGFB, and CXCL9 ( Figure 5A in Figure 3). KLRB1 was significantly associated with ESTIMATE score ( Figure 5 The relative activity of immune cells in the KLRB1-related groups showed that T cells, B cells, NK cells and neutrophils in the KLRB1 high expression group were more active ( Figure 5 C).

[0057] Example 7: Annotation of KLRB1

[0058] Gene set enrichment analysis (GSEA) was performed for the DEGs in the KLRB1-related groups.

[0059] GSEA analysis of KLRB1 showed that nine immune pathways were more active in the KLRB1 high expression group ( Figure 6 ).

[0060] Example 8: Experimental verification of KLRB1

[0061] siRNA sequence for KLRB1:

[0062] si-KLRB1-1: forward CCAACAAGCAATATATGCTGAGTTA (SEQ ID NO: 1);

[0063] si-KLRB1-2: forward ACCTTGGCATCAATTTGCCCTGAAA (SEQ ID NO: 2);

[0064] si-KLRB1-3: forward TGGCATCAATTTGCCCTGAAACTTA (SEQ ID NO: 3).

[0065] qPCR (Quantitative Polymerase Chain Reaction):

[0066] Extraction of total RNA involves harvesting AU565 cells and using an appropriate RNA extraction kit according to the manufacturer's recommendations. cDNA synthesis: Transcribe the extracted RNA into cDNA using a reverse transcription kit. Create specific primers for amplification of the KLRB1 gene. Set up qPCR reaction: Prepare the reaction mixture by adding primers, cDNA, and the appropriate qPCR master mix. qPCR amplification: Perform qPCR amplification using a thermal cycler with appropriate cycling settings. Data analysis: Analyze qPCR data using relevant software to determine the relative expression level of KLRB1 in AU565 cells.

[0067] CCK8 Assay (Cell Counting Kit-8):

[0068] Cell Culture: Culture AU565 cells under appropriate conditions. Cell Seeding: Plate AU565 cells at appropriate density in a 96-well plate. Treatment: Perform specific treatments or experimental modifications on cells. CCK8 Assay Setup: Prepare CCK8 Assay Solution according to the manufacturer's instructions. Incubation: Incubate cells with CCK8 Solution for a set period of time. Absorbance Measurement: Measure the absorbance of the solution using a microplate reader. Analyze absorbance data to determine cell proliferation or viability.

[0069] EdU detection (5-ethynyl-2'-deoxyuridine):

[0070] Treatment and Cell Culture: Culture AU565 cells under specific conditions or with experimental modifications. EdU Labeling: Add EdU to the cell culture mixture and allow to sit for a set period of time. Fixation: Fix cells using an appropriate fixative solution. EdU Detection: Perform EdU detection using the Click-iT EdU Detection Kit following the manufacturer's instructions. Imaging: Take images of cells using a fluorescent microscope. Data Analysis: Examine fluorescent images to determine the proportion of EdU-positive cells.

[0071] Transwell assay:

[0072] Treatment and Cell Culture: Cultivate AU565 cells under specific conditions or make experimental modifications. Transwell Setup: Assemble Transwell inserts with appropriate coatings and pore sizes. Cell Seeding: Seed AU565 cells in the upper chamber of the Transwell insert. Incubation: Incubate cells for a period of time to promote migration or invasion. Fixation and Staining: Fix cells using appropriate staining techniques. Imaging: Image cells using a microscope. Data Analysis: Analyze images to determine if AU565 cells have the ability to migrate or invade.

[0073] The experimental verification results of KLRB1 are shown in Figure 7 qPCR experiments were performed to screen the best siRNA targets ( Figure 7 A in Figure 1). The CCK8 assay of KLRB1 showed that the proliferation ability of breast cancer cells in the two siRNA groups (si-KLRB1-1 and si-KLRB1-2) was enhanced ( Figure 7 B). The EdU experiment of KLRB1 showed that the proliferation ability of breast cancer cells in the two siRNA groups was enhanced ( Figure 7 C and D). Transwell assay of KLRB1 showed that the migration ability of breast cancer cells in the two siRNA groups was enhanced ( Figure 7 E and F). KLRB1 co-culture Transwell experiment showed that the proliferation ability of macrophages in the two siRNA groups was enhanced ( Figure 7 G and H in ).

[0074] Results and Discussion

[0075] Necroptosis can be beneficial or harmful in breast cancer. On the one hand, necroptosis can help clear cancer cells and prevent tumor growth, but on the other hand, it may also increase inflammation and cause tissue damage, thereby helping tumor spread and metastasis. Several studies have shown that breast cancer may lead to dysregulation of necroptosis. For example, in some breast cancer cells, the expression or activity of RIPK3 may be downregulated, thereby hindering the induction of necroptosis. In addition, necroptosis in breast cancer may be affected by the tumor microenvironment. Factors such as stem cell invasion, cytokine signaling, and hypoxia can alter the necroptosis pathway in breast cancer cells. Understanding the importance of necroptosis in breast cancer is crucial for the development of new treatments. An interesting strategy is to selectively induce breast cancer cell death while minimizing damage to healthy organs by targeting the necroptosis pathway. Further research is needed to fully understand the complex interaction between necroptosis and breast cancer progression.

[0076] In the present study, the necroptosis-related pattern was able to effectively distinguish the survival time of breast cancer patients. In addition, KLRB1 was found to be the strongest gene in the necroptosis-related pattern. The KLRB1 gene encodes a protein called KLRB1 or CD161, which is a member of the C-type lectin-like receptor family and a type II transmembrane protein. Natural killer cells (NK cells), T cells, and certain dendritic cell subsets are immune cells that mainly express KLRB1. KLRB1 is involved in immune regulation and cell activation by acting as a receptor for lectin-like transcript 1 (LLT1) ligands. Studies have shown that the expression of KLRB1 is associated with a variety of immune-related functions, such as regulating T cell activation, NK cell cytotoxicity, and cytokine production. KLRB1 is also associated with the occurrence and development of a variety of diseases, including cancer and autoimmune diseases. KLRB1 is also expressed in a variety of cancerous tumors, such as breast cancer. Studies have shown that the expression of KLRB1 in NK cells and T cells in the tumor microenvironment may affect the anti-tumor immune response. Some theories suggest that KLRB1 may regulate the ratio of immune escape to immune surveillance in cancer.

[0077] In the present study, KLRB1 was associated with better survival time in breast cancer patients. KLRB1 can predict the mutation status of 17q12 (DEL17Q12), 8p11.23 (FGFR1), 11q13.3 (EPAS1), 1p36.13 (EPHA2), and 11q23.2 (DRD2). The mutation status of these genes may have an impact on the development, progression, and treatment response of cancer. For example, mutations in FGFR1 are associated with lung cancer and breast cancer, while mutations in EPAS1 are associated with renal cell carcinoma. Understanding specific mutations in these genes can provide valuable insights into the basic biology of cancer and may guide personalized treatment plans. This means that by analyzing the expression of KLRB1, the present invention can determine whether these specific gene mutations are present in breast cancer patients. In addition, KLRB1 is involved in a more immunoactive microenvironment. The results of the present study are consistent with previous studies. The close connection between KLRB1 and immune regulatory factors further demonstrates the predictive value of KLRB1 in immunotherapy.

[0078] Studies have found that necroptosis can affect immunotherapy. Certain immunotherapy drugs can trigger necroptosis in cancer cells, ultimately leading to their death. Necroptosis can improve the effectiveness of immunotherapy by eliminating cancer cells that may be resistant to other forms of cell death. Necroptosis can also trigger an immune response, further enhancing the anti-tumor immune response by activating immune cells and producing cytokines. The role of necroptosis in immunotherapy highlights its potential as a therapeutic target for cancer management. The research presented in this paper may provide new insights into the role of necroptosis in immunotherapy.

[0079] The in vitro validation of the present invention lays a solid foundation for the tumor suppressive effect of KLRB1. KLRB1 can inhibit the proliferation and migration of breast cancer cells. In addition, KLRB1 can also inhibit the recruitment of macrophages. KLRB1 may interact with other molecules or signaling pathways involved in macrophage activation or function. Further research is needed to fully understand how KLRB1 regulates macrophage activity.

[0080] In summary, the present study developed an effective clustering system, namely the necroptosis-related pattern. Necroptosis-related KLRB1 is a powerful tumor suppressor and indicates an immune-active microenvironment. The present study is expected to provide some guidance for exploring necroptosis and cancer immunotherapy.

[0081] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. The use of KLRB1 gene in the treatment of breast cancer, characterized in that: The KLRB1 gene is used as a target in the preparation or screening of breast cancer treatment products.

2. The use according to claim 1, characterized in that: The breast cancer treatment product is a drug or a kit for up-regulating the expression level of the KLRB1 gene, or a drug or a kit for increasing the content or activity of the KLRB1 protein.

3. The use according to claim 1, characterized in that: The breast cancer treatment product comprises a nucleic acid molecule that upregulates the expression level of the KLRB1 gene in tumor cells.

4. The use according to claim 3, characterized in that: The nucleic acid molecule comprises any one or more combinations of siRNA, shRNA, ASO, miRNA or oligonucleotides of the KLRB1 gene.

5. The use according to claim 4, characterized in that: The siRNA sequence of the KLRB1 gene is shown in any one of SEQ ID NOs: 1-2.

6. The use according to claim 1, characterized in that: The KLRB1 gene acts as a potent tumor suppressor, regulates macrophage activity and plays an immunotherapy role in the treatment of breast cancer.

7. A nucleic acid molecule drug for treating breast cancer, characterized in that: The nucleic acid molecule medicine contains a nucleic acid molecule or a pharmaceutically acceptable salt thereof that upregulates the expression level of the KLRB1 gene in tumor cells.

8. The nucleic acid molecule drug for treating breast cancer according to claim 7, characterized in that: The nucleic acid molecule that upregulates the expression level of the KLRB1 gene in tumor cells comprises: any one or more combinations of siRNA, shRNA, ASO, miRNA or oligonucleotides of the KLRB1 gene.

9. The nucleic acid molecule drug for treating breast cancer according to claim 8, characterized in that: The siRNA sequence of the KLRB1 gene is shown in any one of SEQ ID NOs: 1-2.

10. A pharmaceutical composition for treating breast cancer, characterized in that: The pharmaceutical composition comprises the nucleic acid molecule drug for treating breast cancer according to any one of claims 7 to 9 and a pharmaceutically acceptable carrier.

Citation Information

Patent Citations

  • Model for predicting breast cancer immunotherapy effect

    CN115478092A

  • Methods of predicting distant metastasis of lymph node-negative primary breast cancer using biological pathway gene expression analysis

    US20080182246A1